January 2024

Selected coverage of myelodysplastic syndromes and myeloproliferative disease at the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of multiple myeloma from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of acute lymphoblastic leukemia (ALL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12 2023, San Diego, California.

Selected coverage of classical Hodgkin lymphoma (cHL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of mantle cell lymphoma (MCL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Selected coverage of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) from the 65th American Society of Hematology Annual Meeting and Exposition, December 9-12, 2023, San Diego, California.

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Regeneron officials say they are on track to file for FDA approval for the bispecific antibody by the end of 2023.

The results indicated that a substantial proportion of patients, particularly in rural, less educated, and elderly demographics, are insufficiently informed about novel MM treatments, including chimeric antigen receptor (CAR) T-cell therapies and bispecific antibody alternatives.

Robert Rifkin, MD, medical oncologist and hematologist at Rocky Mountain Cancer Centers, shares insight into how the phase 2 Optec study of teclistamab administration in the outpatient setting could help achieve important health equity and quality goals.

Presenters at the American Society of Hematology Annual Meeting and Exposition agreed that novel strategies, such as CRISPR and base editing, have potential to fine-tune the latest immunotherapy advancements to increase the efficacy and durability of a range of treatments.

Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.